Protalix BioTherapeutics (FRA:PBDA) Current Accrued Expense : €10.29 Mil (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics Current Accrued Expense?

Protalix BioTherapeutics's Current Accrued Expense for the quarter that ended in Mar. 2025 was €10.29 Mil.

Protalix BioTherapeutics's quarterly Current Accrued Expense declined from Sep. 2024 (€12.84 Mil) to Dec. 2024 (€10.66 Mil) and declined from Dec. 2024 (€10.66 Mil) to Mar. 2025 (€10.29 Mil).

Protalix BioTherapeutics's annual Current Accrued Expense increased from Dec. 2022 (€9.02 Mil) to Dec. 2023 (€13.23 Mil) but then declined from Dec. 2023 (€13.23 Mil) to Dec. 2024 (€10.66 Mil).

Protalix BioTherapeutics Current Accrued Expense Historical Data

The historical data trend for Protalix BioTherapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Current Accrued Expense Chart

Protalix BioTherapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

9.80

12.75

9.02

13.23

10.66

Protalix BioTherapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															12.96	13.26	12.84	10.66	10.29

Protalix BioTherapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Protalix BioTherapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Protalix BioTherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

PLX:USA

Address

2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601

Website

https://www.protalix.com

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics Headlines

No Headlines